{"schema_version":"secwatch.filing_event.v1","accession":"0001689375-26-000057","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2026-10-14T11:52:00+00:00","discovered_at":"2026-10-14T11:55:00.259251+00:00","generated_at":"2026-10-14T11:55:06.237012+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Entrada's ENTR-601-45 shows safe 5 mg/kg profile, 0.10% dystrophin rise in DMD Cohort 1","bullets":["Cohort 1 of Phase 1/2 ELEVATE-45-201 enrolled 8 ambulatory DMD patients (exon 45 skipping), randomized 3:1 to IV ENTR-601-45 5 mg/kg or placebo on days 1, 43 and 85.","Dystrophin rose a mean 0.10% from baseline in treated patients (n=6, nominal p=0.03) vs a 0.02% mean decrease on placebo; exon skipping rose 0.15% (n=5) vs -0.04% on placebo.","Favorable safety: headache most common TEAE (5 events in 2 participants); 1 participant had 2 serious TEAEs (vomiting, pyrexia) that resolved; no discontinuations; no hypomagnesemia or renal concerns.","No functional benefit seen after three doses, as expected given patient age and baseline function; Q6W dosing equals about nine infusions a year vs 50+ for weekly regimens.","Cohort 2 (10 mg/kg) enrollment complete and dosing ongoing, with data due H1 2027; Cohort 3 up to 15 mg/kg to follow, targeting higher exposure and dystrophin."],"urls":{"canonical":"https://secwatch.observer/filing/0001689375-26-000057","json":"https://secwatch.observer/filing/0001689375-26-000057.json","markdown":"https://secwatch.observer/filing/0001689375-26-000057.md","text":"https://secwatch.observer/filing/0001689375-26-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000168937526000057/0001689375-26-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000168937526000057/trda-20261014.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-14T11:55:06.237012+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}